Meridian Bioscience

Meridian Bioscience Profit per Employee

The Profit per Employee of Meridian Bioscience (VIVO) as of Oct 12, 2026 is 64,331.82 USD. In the previous year, Profit per Employee was 108,192.42 USD — a change of -40.54% (lower).

Profit per Employee

64,331.82USD

YoY

-40.54%

Last updated:

Profit per Employee of Meridian Bioscience is 2022 64,331.82 USD. Profit per Employee of Meridian Bioscience was 2021 108,192.42 USD. It decreases by -40.54% lower compared to the previous year.

The Meridian Bioscience Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2015
53,787.88 USD
Jan 1, 2016
48,787.88 USD
Jan 1, 2017
32,727.27 USD
Jan 1, 2018
36,060.61 USD
Jan 1, 2019
36,969.70 USD
Jan 1, 2020
70,000.00 USD
Jan 1, 2021
108,192.42 USD
Jan 1, 2022
64,331.82 USD
The Meridian Bioscience Profit per Employee history
YEARProfit per EmployeeYoY
64,331.82USD-40.54%
108,192.42USD+54.56%
70,000.00USD+89.34%
36,969.70USD+2.52%
36,060.61USD+10.19%
32,727.27USD-32.92%
48,787.88USD-9.30%
53,787.88USD+2.31%
52,575.76USD—
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Profit per Employee of Meridian Bioscience is 64,331.82 USD in 2022.

Profit per Employee of Meridian Bioscience changed from 108,192.42 USD to 64,331.82 USD, representing a -40.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Workforce — Meridian Bioscience

All Key Metrics — Meridian Bioscience